Cited by 87Inflammasome and immune disordersFatty Acid Research and HealthImmune Response and Inflammation

Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome

Open access
Lopategi, Aritz, Flores-Costa, Roger, Rius, Bibiana, López-Vicario, Cristina, Alcaraz-Quiles, José, Titos, Esther, Clària, Joan·2018·Journal of Leukocyte Biology

Abstract

The prototypic proinflammatory cytokine IL-1β plays a central role in innate immunity and inflammatory disorders. The formation of mature IL-1β from an inactive pro-IL-1β precursor is produced via nonconventional multiprotein complexes called the inflammasomes, of which the most common is the nucleotide-binding domain leucine-rich repeat-containing protein 3 (NLRP3) inflammasome composed by NLRP3, (ASC) apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (CARD), and caspase-1. Specialized proresolving mediators (SPMs) promote resolution of inflammation, which is an essential process to maintain host health. SPMs prevent excessive inflammation by terminating the inflammatory response and returning to tissue homeostasis without immunosupression. This study tested the hypothesis that modulation of the NLRP3 inflammasome in macrophages is one mechanism involved in the SPM-regulated processes during resolution. Our findings demonstrate that the SPM resolvin D2 (RvD2) suppressed the expression of pro-IL-1β and reduced the secretion of mature IL-1β in bone marrow-derived macrophages challenged with LPS+ATP (classical NLRP3 inflammasome model) or LPS+palmitate (lipotoxic model). Similar findings were observed in thioglycolate-elicited peritoneal macrophages, in which RvD2 remarkably reduced ASC oligomerization, inflammasome assembly, and caspase-1 activity. In vivo, in a self-resolving zymosan A-induced peritonitis model, RvD2 blocked the NLRP3 inflammasome leading to reduced release of IL-1β into the exudates, repression of osteopontin, and MCP-1 expression and induction of M2 markers of resolution (i.e., CD206 and arginase-1) in peritoneal macrophages. RvD2 inhibitory actions were receptor mediated and were abrogated by a selective GPR18 antagonist. Together, these findings support the hypothesis that SPMs have the ability to inhibit the priming and to expedite the deactivation of the NLRP3 inflammasome in macrophages during the resolution process. Resolvin D2 modulates the NLRP3 inflammasome and the production of IL-1β in macrophages during resolution of inflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jlb.3hi0517-206rr

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 31 · Cited by 87

Authors
Lopategi, A., Flores-Costa, R., Rius, B., López-Vicario, C., Alcaraz-Quiles, J., Titos, E., & Clària, J.
Affiliations
  • Hospital Clínic de Barcelona (ES)
  • Department of Biochemistry and Molecular Genetics, Hospital Clínic–IDIBAPS , Barcelona, Spain
  • European Foundation for the Study of Chronic Liver Failure (ES)
Corresponding author
  • Lopategi, Aritz
  • Clària, Joan
Venue
Journal of Leukocyte Biology
Published
2018-03-30
Volume
105
Issue
1
Pages
25-36
ISSN
  • 0741-5400 (ISSN-L)
  • 1938-3673
OpenAlex
W2795164109
Cited by
87
References
31
Citations by year
2026: 7 · 2025: 6 · 2024: 5 · 2023: 11 · 2022: 13 · 2021: 18 · 2020: 16 · 2019: 8 · 2018: 3
FWCI
4.00
Type
journal article
Language
en
Open access
Locations
  • Journal of Leukocyte Biology (publishedVersion)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
Funders
  • Spanish MEC (SAF15-63674-R, PIE14/00045)
  • ERDF
  • CIBERehd
  • European Regional Development Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords
specialized pro-resolving mediators, resolvin D2, NLRP3 inflammasome, macrophages, IL-1β, caspase-1, ASC oligomerization, inflammation resolution, GPR18, M2 macrophages, lipotoxicity, osteopontin, MCP-1
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Adenosine Triphosphate, Animals, Bone Marrow Cells, Docosahexaenoic Acids, Inflammation, Lipopolysaccharides, Macrophage Activation, Male, Mice, Inbred C57BL, Phenotype, Zymosan, Macrophages, Peritoneal, Palmitic Acid, Caspase 1, Inflammasomes, Caspase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review